JP2024546497A5 - - Google Patents
Info
- Publication number
- JP2024546497A5 JP2024546497A5 JP2024535848A JP2024535848A JP2024546497A5 JP 2024546497 A5 JP2024546497 A5 JP 2024546497A5 JP 2024535848 A JP2024535848 A JP 2024535848A JP 2024535848 A JP2024535848 A JP 2024535848A JP 2024546497 A5 JP2024546497 A5 JP 2024546497A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug conjugate
- pharmaceutical composition
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025271167A JP2026053502A (ja) | 2021-12-17 | 2025-12-22 | Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111551337 | 2021-12-17 | ||
| CN202111551337.8 | 2021-12-17 | ||
| PCT/CN2022/139637 WO2023109953A1 (zh) | 2021-12-17 | 2022-12-16 | 靶向Claudin18.2的抗体-药物偶联物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025271167A Division JP2026053502A (ja) | 2021-12-17 | 2025-12-22 | Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024546497A JP2024546497A (ja) | 2024-12-24 |
| JP2024546497A5 true JP2024546497A5 (https=) | 2025-11-11 |
| JP7796230B2 JP7796230B2 (ja) | 2026-01-08 |
Family
ID=86774867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024535848A Active JP7796230B2 (ja) | 2021-12-17 | 2022-12-16 | Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体 |
| JP2025271167A Pending JP2026053502A (ja) | 2021-12-17 | 2025-12-22 | Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025271167A Pending JP2026053502A (ja) | 2021-12-17 | 2025-12-22 | Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250073347A1 (https=) |
| EP (1) | EP4450521A1 (https=) |
| JP (2) | JP7796230B2 (https=) |
| KR (1) | KR20240133715A (https=) |
| CN (1) | CN119173534A (https=) |
| AU (1) | AU2022416272A1 (https=) |
| CA (1) | CA3242970A1 (https=) |
| TW (1) | TWI869741B (https=) |
| WO (1) | WO2023109953A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7796230B2 (ja) * | 2021-12-17 | 2026-01-08 | フォートビタ バイオロジクス（シンガポール）プライベート リミティド | Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体 |
| EP4623936A1 (en) * | 2022-11-22 | 2025-10-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| CN119591708A (zh) * | 2023-09-08 | 2025-03-11 | 成都临界点生物科技有限公司 | 抗Claudin18.2人源化单域抗体 |
| WO2025077815A1 (zh) * | 2023-10-11 | 2025-04-17 | 福佑泰生物制药（新加坡）公司 | 靶向Claudin18.2的抗体-药物偶联物联合治疗癌症的方法 |
| TW202532100A (zh) * | 2023-12-22 | 2025-08-16 | 大陸商信達生物製藥（蘇州）有限公司 | 靶向b7h3和egfr的雙特異性抗體-藥物偶聯物及其應用 |
| WO2025149029A1 (zh) * | 2024-01-12 | 2025-07-17 | 信达生物制药(苏州)有限公司 | 抗cd28抗体及其用途 |
| CN119345386B (zh) * | 2024-10-25 | 2025-12-09 | 华润生物医药有限公司 | 靶向Claudin18.2的抗体药物耦联物及其用途 |
| CN121130103A (zh) * | 2025-11-05 | 2025-12-16 | 上海以岭药业有限公司 | 靶向cldn 18.2的抗体药物偶联物及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9701753B2 (en) * | 2013-03-11 | 2017-07-11 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
| CN106589127A (zh) * | 2015-10-16 | 2017-04-26 | 钜川生物医药 | 一种pcsk9抗体及其制备方法和应用 |
| NZ762505A (en) * | 2017-09-29 | 2026-03-27 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| WO2019242505A1 (zh) * | 2018-06-17 | 2019-12-26 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| SG11202106765XA (en) * | 2018-12-27 | 2021-07-29 | Gigagen Inc | Anti-pd-1 binding proteins and methods of use thereof |
| CN119350498A (zh) * | 2018-12-28 | 2025-01-24 | 四川科伦博泰生物医药股份有限公司 | 一种抗体及其用途 |
| CN113631229B (zh) * | 2019-03-25 | 2025-09-23 | 第一三共株式会社 | 抗体－吡咯并苯并二氮杂卓衍生物偶联物 |
| CN112138171B (zh) | 2019-06-28 | 2024-09-24 | 泰州复旦张江药业有限公司 | 抗体偶联药物、其中间体、制备方法及应用 |
| KR102773187B1 (ko) * | 2019-07-12 | 2025-02-27 | 퓨쳐진 바이오파머쓰티컬 (베이징) 코., 엘티디. | Cldn18.2 항체 및 이의 용도 |
| CN112707965A (zh) * | 2019-09-30 | 2021-04-27 | 和铂医药(苏州)有限公司 | 靶向cldn18.2的抗体及其制备方法和应用 |
| US20230054458A1 (en) | 2019-12-12 | 2023-02-23 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-claudin antibody-drug conjugate and pharmaceutical use thereof |
| US20230235047A1 (en) * | 2020-06-19 | 2023-07-27 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-claudin18.2 antibody and use thereof |
| JP2023541637A (ja) | 2020-09-15 | 2023-10-03 | シンアフィックス ビー．ブイ． | 抗体－エクサテカンコンジュゲート |
| US20240293457A1 (en) * | 2020-12-25 | 2024-09-05 | Innovent Biologics (Suzhou) Co., Ltd. | Claudin18.2 chimeric antigen receptor and use thereof |
| JP7796230B2 (ja) * | 2021-12-17 | 2026-01-08 | フォートビタ バイオロジクス（シンガポール）プライベート リミティド | Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体 |
-
2022
- 2022-12-16 JP JP2024535848A patent/JP7796230B2/ja active Active
- 2022-12-16 CN CN202280083295.6A patent/CN119173534A/zh active Pending
- 2022-12-16 US US18/719,023 patent/US20250073347A1/en active Pending
- 2022-12-16 WO PCT/CN2022/139637 patent/WO2023109953A1/zh not_active Ceased
- 2022-12-16 KR KR1020247023670A patent/KR20240133715A/ko active Pending
- 2022-12-16 AU AU2022416272A patent/AU2022416272A1/en active Pending
- 2022-12-16 TW TW111148546A patent/TWI869741B/zh active
- 2022-12-16 EP EP22906698.0A patent/EP4450521A1/en active Pending
- 2022-12-16 CA CA3242970A patent/CA3242970A1/en active Pending
-
2025
- 2025-12-22 JP JP2025271167A patent/JP2026053502A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024546497A5 (https=) | ||
| JP2020019787A5 (https=) | ||
| JP2022191301A5 (https=) | ||
| TWI865337B (zh) | 抗體-藥物結合物之有效的製造方法 | |
| JP2019532056A5 (https=) | ||
| JP2025111463A5 (https=) | ||
| JP2024109678A5 (https=) | ||
| JP2021527640A5 (https=) | ||
| JP2020509027A5 (https=) | ||
| JP2025131696A5 (https=) | ||
| JP2024167313A5 (https=) | ||
| JP2019107018A5 (https=) | ||
| JP2023535598A5 (https=) | ||
| RU2018119296A (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
| JP2022523442A5 (https=) | ||
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| JP2025038088A5 (https=) | ||
| JP2024540148A5 (https=) | ||
| JP2023519776A5 (https=) | ||
| JP2025501775A5 (https=) | ||
| NZ592436A (en) | Treatment with anti-alpha2 integrin antibodies | |
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| JP2025015580A5 (https=) | ||
| JP2025539841A5 (https=) | ||
| JP2024506708A5 (https=) |